Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

Genetics Investing

Affimed (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing of its previously announced public offering of 13,225,000 of its common shares at a public offering price of $2.00 per common share. As quoted in the press release: The total includes 1,725,000 common shares issued …

As quoted in the press release:

The total includes 1,725,000 common shares issued pursuant to the underwriters’ option to purchase additional shares. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the public offering are expected to be approximately $24.5 million. Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers.

Click here to read the full press release.

affimed cancer clinical-stage biopharmaceutical clinical-stage biopharmaceutical company net proceeds public offering wells fargo wells fargo securities Genetics Investing